Director, McGill International TB Centre and
Director of McGill Global Health Programs
Combating antimicrobial resistance (AMR)
Tuberculosis (TB) is the number one global infectious disease killer today and drug resistance is a huge problem. Drug-resistant TB has a survival rate of barely 50 percent. Even though more than half a million people have drug-resistant TB, most patients are not being tested for drug resistance. To change this, we have to fundamentally agree that all patients with TB deserve drug-resistance screening tests and that all patients found to have drug-resistant TB will receive an appropriate treatment regimen. We need to work together to drive more change. Because all of us need to be resistance fighters.